Evusheld (Cilgavimab | Tixagevimab)

Evusheld is a combination of cilgavimab and tixagevimab, used for pre-exposure prophylaxis of COVID-19. This intramuscular injection is manufactured by AstraZeneca AB in the EU.

Evushel is designed to help prevent COVID-19 in individuals who may not respond adequately to vaccination. It contains two monoclonal antibodies, cilgavimab and tixagevimab, which work together to provide protection against the virus. This medication is typically administered as a preventive measure for those at high risk of exposure or severe infection.

Common effects of Evusheld may include reactions at the injection site, such as pain, swelling, or redness. Some individuals might experience general side effects like headache, fatigue, or muscle pain. These effects are usually mild and temporary.

Evusheld should be used under the guidance of a healthcare professional. It is important to inform your healthcare provider about any allergies or medical conditions before administration. Always follow the prescribed storage and handling instructions to maintain the medication's effectiveness.

Evusheld may interact with other medications, particularly those that affect the immune system. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions. Additionally, avoid alcohol consumption around the time of administration to minimize the risk of side effects.